Pharmaceutical Reviews Update 8

See Pharmaceutical Reviews Update – Issue 8 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:

• details around when patient groups may be re-engaged in the CADTH Common Drug Review (CDR) process following an initial call for patient input
• an announcement on a new review process for biosimilar submissions
• update on the proposal to integrate key functions of the Cancer Drug Implementation Advisory Committee into the CADTH pan-Canadian Oncology Drug Review (pCODR) Process
• updates specific to CDR, specifically:
  • the redaction request process
  • the advance notification process
  • clinical review templates
  • the addition of a representative from Canadian Blood Services (CBS) to the CADTH Drug Policy Advisory Committee (DPAC) Formulary Working Group
  • revisions to the Procedure and Submission Guidelines for the CADTH Common Drug Review.